Method of photodynamic therapy of malignant growths

FIELD: medicine.

SUBSTANCE: invention concerns medicine, oncology, and is applicable for photodynamic therapy of malignant growths. That is ensured by introducing a photosensitiser and conducting light illumination of the new growth at wave length corresponding to a maximum absorption of chlorine derivatives. The photosensitiser is presented by a gelatinous capsule with powder microparticles of chlorine derivatives mixed with lyophilised spirulina platensis. Each powder microparticle is coated with a protective acid-resistant film. The gelatinous capsule is introduced orally. Each gelatinous capsule contains the ingredients in the following proportions (Mg): chlorine derivatives - 1-1.5; spirulina platensis - 100-150; protective acid-resistant film - 50-75; calcium stearate - 0.5-0.75.

EFFECT: method enables providing higher clinical and preventative effectiveness in malignant new growths.

8 cl, 1 dwg, 3 ex

 

The invention relates to medicine and can be used in Oncology for the treatment and prevention of malignant tumors of the skin and mucous membranes, as well as in ophthalmology for the treatment and prevention of intraocular tumors.

There is a method of photodynamic therapy of malignant tumors, including drug and laser irradiation of tumors (see RF patent №2161053).

The disadvantage of this method is the injury of blood vessels at intravenous administration of the drug, the risk of Contracting viral diseases, allergic reactions and the high cost of the drug.

The technical nature closest to the proposed invention is a method of photodynamic therapy of malignant tumors, including drug and laser irradiation of tumors, and as a drug on an empty stomach oral taking the derivative of porphyrin plant origin at a dose of 10.0 mg/kg, and laser irradiation is carried out after 3-4 hours with a wavelength corresponding to maximum absorption derived porphyrin light radiation (see RF patent №2294224, CL A61N 5/067 from 26.04.2005,).

However, the composition of the drug and its implementation in the known method does not allow to effectively carry out the accumulation of photosensitizer-FS in crit the immediate vicinity of the body, as part of the preparation there is no means of the directed delivery of the photosensitizer to the critical organ. In addition, delivery of the drug to a critical body depends on many parameters.

The technical result is to increase the effectiveness of treatment and prevention of malignant neoplasms by optimizing delivery of the drug to the critical organ.

This is achieved by the fact that in the method of photodynamic therapy of malignant tumors, including the introduction of a photosensitizer and light irradiation of tumors, which is carried out after the above introduction with the wavelength corresponding to maximum absorption derivative of chlorin, according to the invention as a photosensitizer use a gelatin capsule filled with powder microparticles derived from chlorine mixed with freeze-dried spirulina platensis, each microparticle powder coated with acid-resistant protective film, and the introduction of gelatine capsules perform oral, in addition, as the acid-resistant protective film using a coating type collicut", and to prevent adhesion of microparticles using powder calcium stearate, and each gelatin capsule contains components in the following weight ratios (mg:

Derivatives of chlorin1-1,5
Spirulina platensis100-150
Protective acid-resistant film50-75

Calcium stearate - 0,5-0,75, in addition, as a light irradiation using led or laser irradiation, and as chlorins derived using chlorin E6 in the form of Leguminosae salt or pheophytin "a", and the wavelength of the light irradiation take equal 650-670 nm led irradiation or 662 nm laser irradiation, and the dose is 300 and 900 j/cm2, light irradiation is carried out after 3-4 hours after injection of the photosensitizer - FS. The comparison of the proposed technical solutions with known suggests the criterion of "novelty", and the lack of analogues distinctive signs under the criterion of "inventive step". Preliminary tests suggest about the possibility of wide industrial use.

Figure 1 shows the dependence of the optical density D of the photosensitizers of wavelength λ for two different types.

The method is as follows.

In the morning on an empty stomach, the patient takes oral relatinoships, contains components in the following weight ratios (mg:

Derivatives of chlorin1-1,5
Spirulina platensis100-300
Protective acid-resistant film50-75
Calcium stearate0.5 to 1.5

And as a photosensitizer use a gelatin capsule filled with powder microparticles derived from chlorine mixed with freeze-dried spirulina platensis, and each particle of the powder is covered with a protective acid-resistant film, which is used as the coating type collicut".

It should be noted that to prevent adhesion of microparticles using powder calcium stearate, as a light irradiation using led or laser irradiation, and as chlorins derived using chlorin E6 in the form of Leguminosae salt or pheophytin "a".

It should be noted that the wavelength of the light irradiation take equal 650-670 nm led irradiation or 662 nm laser irradiation, and the dose is 300 and 900 j/cm2moreover , the radiation dose is less than 300 j/cm2not effective, and the ri dose of more than 900 j/cm 2causes damage to the surrounding healthy tissue is burned. In the treatment of tumors height of 1-1,5 mm using a dose of 300 j/cm2in the treatment of tumors height of 2-3 mm up to 600 j/cm2and in the treatment of tumors up to 5 mm up to 900 j/cm2. It should be noted that the irradiation region tumors spend 3-4 hours after administration of the photosensitizer, and the visualization of tumors is carried out using diode lamp type "lamed".

Example 1.

Patient C., born in 1974 Diagnosed with Lymphoma with invasion of the mediastinum. Received 2 courses of chemotherapy and radiation therapy. Upon entering reabilitaciju condition was relatively satisfactory. Had complaints of weakness and malaise.

It was held above the impact from the application of the photosensitizer and the subsequent light exposure. The use of capsules with chlorin E6 resulted in improved immunological parameters and General condition.

On immunological parameters has a positive dynamics: SRS increased from 438 to 740, CD4 increased from 96 to 155, the number of lymphocytes increased from 0.6 to 1.0.

Example 2.

Patient R., born in 1973.. Diagnosis: malignant thymoma mediastinum. After from 2007 - metastases in the lungs.

The use of capsules in complex therapy of lead is about the improvement of the General condition, reducing the level of intoxication, decrease nausea, dyspeptic symptoms, stabilization of the cancer process.

Example 3.

Often suffer from catarrhal diseases of the child as at the age of 6 years, after taking the capsules with chlorin E6 in the half dose for a week in the following months was not sick. Health and physical activity has improved.

Presented in figure 1 characteristics of the electronic absorption spectra of alcoholic extracts of spirulina-1 and spirulina with the addition of pheophytin-2 show more effective the influence of the latter due to the greater concentration of the photosensitizer.

Thus in the present invention is achieved by the technical result.

1. The method of photodynamic therapy of malignant tumors, including the introduction of a photosensitizer and light irradiation of tumors, which is carried out after the above introduction, the wavelength corresponding to maximum absorption derivative of chlorin, characterized in that the photosensitizer used a gelatin capsule filled with powder microparticles derived from chlorine mixed with freeze-dried spirulina platensis, each microparticle powder coated with acid-resistant protective film, and the introduction of a gelatin capsule carried the t oral, each gelatin capsule contains components in the following weight ratios (mg): derivatives of chlorin - 1-1,5; spirulina platensis - 100-150; acid-resistant protective film - 50-75; calcium stearate and 0.5-0.75 in.

2. The method according to claim 1, characterized in that as the acid-resistant protective film using a coating type collicut".

3. The method according to claim 1, characterized in that to prevent adhesion of microparticles using powder calcium stearate.

4. The method according to claim 1, characterized in that the light irradiation using led or laser irradiation.

5. The method according to claim 1, characterized in that as chlorins derived using chlorin E6 in the form of Leguminosae salt or pheophytin "a".

6. The method according to claim 4, characterized in that the wavelength of the light irradiation take equal 650-670 nm led irradiation or 662 nm laser irradiation.

7. The method according to claim 1, characterized in that the irradiation dose is 300 and 900 j/cm2.

8. The method according to claim 1, characterized in that the light irradiation is carried out after 3-4 h after injection of the photosensitizer.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, and concerns pharmaceutical compositions able to induce cancer cell apoptosis for diagnosing and treating B-cell chronic lymphocytic leukaemia. Substance of the inventions involves the pharmaceutical compositions for treating B-cell chronic lymphocytic leukaemia containing an active ingredient presented by a humanised monoclonal antibody T1h from a secreting hybridoma IOR-TIA under depositary No. ECACC 96112640, identifying a leukocyte differentiation antigen CD6. A diagnostic reagent also contains said antibody.

EFFECT: advantage of the group of inventions consists in higher specific activity.

11 cl, 4 ex, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and medicine and concerns triindolyl methane derivatives of formula

and as anticancer drugs showing cytotoxic, apoptotic action on tumour cells, and also blocking NFkB transcription factor activity.

EFFECT: compounds exhibit high anticancer activity.

4 dwg, 3 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and veterinary science. A method involves sequential intravenous introduction of a binary catalytic system (BCS): an oxidation catalyst - a metal complex and an oxidation substratum - ascorbic acid (AA). The oxidation catalyst is introduced in a maximally tolerable or lower doses, and AA - in doses related to molar ratio of the metal complex: AK=1:10. The method also involves local hyperthermia of the tumour with using near infra-red laser emission. The tumour temperature is maintained within the range of 43-45°C by adjusting laser power density. The emission is terminated after achieving the minimum power density maintaining the tumour temperature within the preset temperature range. The declared device comprises a near infra-red laser with emissive power switch-on, switch-off and adjustment systems, and optical system of laser beam formation, a tumour temperature control system with its output connected both with an input of a laser negative feedback system, a laser power density control system. The device comprises an additionally adjustable power density discriminator. An input of the laser power density discriminator is connected with an output of the laser power density control system. The output of the discriminator is connected to an input of the laser switch-off system.

EFFECT: invention provides higher clinical effectiveness.

5 cl, 1 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine and is applicable in the form of liposome-containing compounds for cancer therapy. A liposome contains one or more phosphatidylcholines, a first derivative of N-(ω)-dicarboxylic acid and phosphatidylethanolamine, an orientation modified derivative of N-(ω)-dicarboxylic acid and phosphatidylethanolamine, an encapsulated therapeutic agent and at least one additional lipid which represents cholesterol or a cholesterol derivative. The orientation modified derivative of N-(ω)-dicarboxylic acid and phosphatidylethanolamine contains an orientation ligand attached to a second derivative of N-(ω)-dicarboxylic acid and phosphatidylethanolamine. The first derivative of N-(ω)-dicarboxylic acid and phosphatidylethanolamine is presented by formula 1,

and the second derivative of N-(ω)-dicarboxylic acid and phosphatidylethanolamine is presented by formula 3, . The orientation ligand preferentially represents transferring, while the encapsulated therapeutic agent is oxalyplatine. The liposome is free from non-modified phosphatidylethanolamine, egg phosphatidylcholine or hydrophilic polymer used to prolong a half lifetime of the liposome in a circulatory channel, and the orientation ligand is other than an intact antibody. What is also described is a method of producing the liposome and a method of treating cancer with using it.

EFFECT: group of inventions provides better target delivery of the therapeutic substance in the tumour cells.

113 cl, 25 dwg, 4 tbl, 30 ex

FIELD: chemistry.

SUBSTANCE: invention relates to peptide-based compounds containing three-member rings containing a heteroatom, which efficiently and selectively inhibit specific activity of N-terminal nucleophilic (Ntn) hydrolase, bonded with a proteasome. The peptide-based compounds contain epoxide and are functionalised at the N-end.

EFFECT: peptide-based compounds exhibit anti-inflammatory properties and cell proliferation inhibition, oral administration of said peptide-based proteasome inhibitors is possible owing to bioavailability thereof.

23 cl, 14 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel derivatives of the anti-tumour antibiotic of the aureolic acid olivomycin A group, having anti-tumour activity and low toxicity, and synthesis method thereof. The invention also relates to a method of producing derivatives of the antibiotic of the aureolic acid olivomycin A group, involving selective oxidation of the side chain of olivomycin A aglycone through reaction with sodium periodate, followed by amidation of the obtained key intermediate 1'-des-(2,3-dihydroxy-n-butyroyl)-1'-carboxyolivomycin A with corresponding amines in the presence of a condensing agent.

EFFECT: disclosed compounds have marked anti-tumour activity and low toxicity compared with the original olivomycin A.

2 cl, 9 ex, 1 dwg, 6 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula (I), having histone deacetylase (HDAC) enzyme inhibiting action, stereoisomers, hydrates, solvates and pharmaceutically acceptable salts thereof, compounds of formula (II), compounds selected from a list, a method of producing compounds of formula (I), a pharmaceutical composition, an inhibition method and methods of treating using compounds of formula (I). In formulae

and

R denotes substituted or unsubstituted groups selected from (C6-C10)aryl, (C3-C12)cycloalkyl, heteroaryl, (C6-C10)aryl (C1-C6)alkyl and heterocyclyl; where the heterocyclyl hereinafter is a 5-10-member ring radical which consists of carbon atoms and 1-5 heteroatoms selected from nitrogen, oxygen and sulphur, and heteroaryl hereinafter is an aromatic heterocyclyl, and each aryl, cycloalkyl, heteroaryl, arylalkyl and heterocyclyl can be substituted with one or more substitutes selected from halogens, including fluorine, chlorine, bromine, iodine, (C1-C6)alkyl, (C1-C6)alkoxy, (C6-C10)aryl, halogen(C1-C6)alkyl, (C6-C10)aryl(C1-C6)alkoxy, -O-(C3-C12)cycloalkyl, -O-CH2-(C3-C12)cycloalkyl, hydroxyl, NRaRb and ORa, where Ra and Rb independently denote (C1-C6)alkyl and aryl; R1 denotes (C6-C10)aryl; R2 and R3 independently denote hydrogen, (C1-C6)alkyl, -COOR5, -CONR5R6, -CH2NR5R6, -CH2CH2NR5R6, -CH2CH2OH or -CH2OH; provided that one of R5 or R6 is hydrogen or unsubstituted alkyl, the other is neither hydrogen nor unsubstituted alkyl; R5 and R6 independently denote hydrogen, (C1-C6)alkyl, (C3-C12)cycloalkyl, (C6-C10)aryl, (C6-C10)aryl(C1-C6)alkyl, heteroaryl or heteroaryl(C1-C6)alkyl, which can be unsubstituted or substituted; or R5 and R6 can be combined to form a saturated or unsaturated 3-8-member ring having 0-2 heteroatoms, including N, O or S; where the heteroaryl hereinafter is a 5-10-member ring radical consisting of carbon atoms and 1-5 heteroatoms selected from nitrogen, oxygen and sulphur, and each alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl can be substituted with one or more substitutes selected from halogen, including chlorine, fluorine, bromine or iodine,(C1-C6)alkoxy and NRaRb; R4 denotes OH, (C6-C10)aryl, ortho-substituted aniline or amino (C6-C10) aryl, which can be optionally substituted with one or more groups selected from halogens, including fluorine, chlorine, bromine, iodine, hydroxyl, amino groups or (C6-C10)aryl; X denotes -NR7-, -CONR7- or -N R7CO; R7 denotes hydrogen or (C1-C6)alkyl; Y denotes (C6-C10)aryl or (C6-C10)aryl(C2-C6)alkenyl; m is an integer from 0 to 1; n is an integer from 0 to 1; o is an integer from 0 to 7; and p is an integer from 0 to 1.

EFFECT: improved method.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely oncology, and is applicable for treating rectal cancer with synchronous remote metastases. That is ensured by radiation therapy together with radio modifiers and combined with chemotherapy followed by radical resection of a primary tumour and remote metastases. The radio modifiers are presented by the intrarectal introduction of metronidazole as a part of a composite mixture containing sodium alginate and 2% dimethylsulphoxide, and also local microwave hyperthermia. The chemotherapy is presented by a two-day intensive course of chemotherapy FOLFOX6 involving high doses of platinum and 5-fluorouracil in the form of the 48-hour infusion.

EFFECT: method allows reducing total length of treatment, enabling a complete course of effective preoperative radiation chemotherapy with minimum toxicity in a relatively short time, performing earlier sphincter-preserving operations with well-timed resection of the primary tumour, regional and remote metastases ensured by implementing mechanisms, chemosensitisation and synergic effect of said radio sensitising agents.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to cell biology. Dopamine and/or its synthetic analogues, particularly substituted 3,4-dihydro-2(1H)-pyrimidinthione is applied as a cytotoxic agent having an effect on human cancer cells in culture.

EFFECT: presented substances can find application in medicine as a base for developing dosage forms used for therapy of malignant growths.

5 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound having chemical structure of formula II , all salts and stereoisomers thereof, where the value of radicals D, A2 and B are as described in paragraph 1 of the claim. The invention also relates to a composition having activity as a c-kit and c-fms modulator, a method of treating a subject suffering from a disease or condition mediated by c-kit and c-fms and a kit for modulating c-kit and c-fms.

EFFECT: novel compounds which can be useful in treating c-kit-mediated diseases or conditions and/or c-fms-mediated diseases or conditions are obtained and described.

21 cl, 44 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, specifically surgery, physiotherapy. The method involves septic wound exposure to light. That is ensured by monochrome non-coherent light-emitting diode radiation at wave length 470±10 nm. A single radiation dose makes 2.5-4.0 J/cm2.

EFFECT: method reduces length of pain management, provides an adequately shorter period of the phase I wound process and faster transition of the II to III phases that leads to the onset of granulation and regional epithelisation in an adequately shorter period, reduces the microbial contamination level ensured by activation of cell and humoral immunity providing reliable decrease of anti-inflammatory cytokines.

2 ex, 7 tbl

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and veterinary science. A method involves sequential intravenous introduction of a binary catalytic system (BCS): an oxidation catalyst - a metal complex and an oxidation substratum - ascorbic acid (AA). The oxidation catalyst is introduced in a maximally tolerable or lower doses, and AA - in doses related to molar ratio of the metal complex: AK=1:10. The method also involves local hyperthermia of the tumour with using near infra-red laser emission. The tumour temperature is maintained within the range of 43-45°C by adjusting laser power density. The emission is terminated after achieving the minimum power density maintaining the tumour temperature within the preset temperature range. The declared device comprises a near infra-red laser with emissive power switch-on, switch-off and adjustment systems, and optical system of laser beam formation, a tumour temperature control system with its output connected both with an input of a laser negative feedback system, a laser power density control system. The device comprises an additionally adjustable power density discriminator. An input of the laser power density discriminator is connected with an output of the laser power density control system. The output of the discriminator is connected to an input of the laser switch-off system.

EFFECT: invention provides higher clinical effectiveness.

5 cl, 1 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely dermatovenerology and is applicable for treating chronic infectious urethritis complicated by prostatitis. That is ensured by taking azithromycin 1.0 g (sumamed) once a day in 1st-7th-14th days combined with the complex therapy. The complex therapy involves rectal suppositories Dalargex, 1 suppository daily at bedtime No.10, prostate massage, rectal laser therapy and daily application of fluoroquinolone - gemifloxacin (factive) 1 tab. (320 mg) a day for 14 days.

EFFECT: method enables prolonged remission of the disease, higher life quality of the patients, recovers the reproductive function due to improved eradication of the opportunistic flora in the prostate secretion contents.

4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely urology, is applicable for treating chronic cystitis. That is ensured by drug instillations into a bladder. In addition, the instillation is preceded by endovesical mucosal exposure to laser light of wave length 0.62 mcm. The instillation is followed by pubic exposure to laser light of wave length 0.86 mcm within a projection of the bladder. The duration of each procedure is 7 minutes; the therapeutic course is 10-12 procedures.

EFFECT: method provides higher clinical effectiveness ensured by pain pulse interruption and improved microcirculation and consequently prolonged drug staying in the bladder cavity as a result of the exposure to laser light before the instillation, and also by deeper drug penetration in bladder tissue as a result the epicutaneous exposure to laser light after the instillation.

1 dwg, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely therapy, and is applicable for correction of cardiovascular disorders accompanying metabolic syndrome in the patients suffering osteoarthrosis. It involves the supravenous blood exposure at wave length 405 nm, light guide tip power 1.5 mWt, length of a procedure 5 minutes. It is followed by contact joints exposure at wave length 630 nm, pulse power 10 Wt, frequency 80 Hz. Knee joints are exposed for 2 minutes from 4 sides and with using a lability technique by beam scanning along an joint space for 2 minutes. Hip joints are exposed through a projection of inguinal ligament, greater trochanter, ischial tuberosity for 2 minutes and with using a lability technique by beam scanning along the joint space for 4 minutes. The therapeutic course includes 10 daily sessions.

EFFECT: method allows providing prolonged remission and lowered drug load ensured by eliminating inflammatory activity, lipid spectrum, coagulation hemostasis and carbohydrate metabolism disorders.

19 tbl

FIELD: medicine.

SUBSTANCE: invention refers to physiotherapeutic apparatuses and is applicable for vitality recovery after damaging exercises and mental overload, and for treating various diseases by laser reflex therapy. A presented apparatus comprises a handle body which integrates a laser diode coupled with a control unit with emission brought outside through an outlet on a pointed handle tip. A side surface of the handle comprises a general electrode also connected with the control unit. The control unit is connected to a power supply unit. In the presented apparatus, the power supply unit and the control unit are integrated in the handle, on an internal side surface of the outlet, there is an acupuncture point detector represented by a thin metal core of the diameter no more than 1 mm one end of which is bent so that it gets into a laser beam, and another one is connected to the control unit.

EFFECT: invention allows detecting the acupuncture points more precisely with using a laser beam.

1 dwg

FIELD: medicine.

SUBSTANCE: claimed invention relates to ophthalmology, namely to ophthalmic oncology and is intended for organ-preserving treatment of intraocular tumours. Transpupillary PDT is performed. After 3-20 days treansscleral PDT is carried out. After tumour devitalisation, total vitrectomy and endoresection of tumour is performed. Vitreous cavity is filled with substitute of vitreous body and laser coagulation of retina is carried out.

EFFECT: method ensures radical complete destruction of tumour with extension of indications to organ-preserving treatment with recovery of functional reserves of eye.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medical equipment. Device for treatment of amblyopia by means of pattern- and colour-stimulation contains tube, covered with mirror plates, light-transparent multi-coloured elements of arbitrary shape and light source. Two replaceable units with multi-coloured elements with particle size 3-4 mm with vision acuity ≥0.1 and 6-7 mm with vision acuity <0.1 are used. As light source multi-colour LED is used.

EFFECT: application of claimed device will make it possible to increase efficiency of stimulation and will make it possible to carry out treatment of patients with different vision acuity.

2 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine and medical equipment, namely to devices for cosmetic and/or therapeutic human or animal skin preparation for the purpose of depilation and/or hair growth cessation or reduction. A device comprises a radiation source and radiation beam deflectors. Said deflectors comprises refractors through which a radiation beam passes, drivers designed for moving said refractors at least in two orthogonal directions, and control units designed for control said drivers to deviate said radiation beam. The control units are designed to control said drivers to enable the programmed movement in said orthogonal directions for scanning of said radiation beam along a skin surface for processing the area to be prepared.

EFFECT: use of the invention shall enable real-time skin preparation without multiple emitter switch during preparation.

11 cl, 7 dwg

FIELD: agriculture.

SUBSTANCE: invention relates to animal husbandry, in particular, to methods of prevention transport stress of pigs. The method consists in activation of physiological adaptation mechanisms by daily exposure of pulsed low-intensity infrared radiation on the skin surface in the zone of localisation of the biologically active centers (BAC) № 4, №23, №33, №37, №50, №59 with frequency of 600 Hz, with a capacity of 10 mW with exposure of 256 seconds to each center, ten days prior to transportation.

EFFECT: method enables to increase the level of BAC biopotential, reduce the loss of body weight during transportation and improve meat quality obtained after slaughter carcasses.

1 dwg, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry, in particular - to composition of a medication possessing antiviral action and manufactured in the form of solid gelatine capsules as well as to such medication production method. The antiviral medication contains granules the active substance represented by sodium salt of 2-methylthio-6-nitro-1,2,4-triazolo[5,1-c]-1,2,4-triazin-7-on, a dehydrate and physiologically acceptable accessory substances: starch as filler and disintegrant and talc as the anti-friction substance. The granules size is within the range of 0.5-0.63 mm. The gelatine capsules weight is from 0.290 to 0.300 g. The method for production of the antiviral medication in the form of granules contained in gelatine capsules is implemented by way of wet granulation.

EFFECT: according to the invention, the medication is noted for a pronounced virus-inhibiting action, satisfactory organoleptic properties and pharmacological safety and extends the arsenal of antiviral medications.

12 cl, 3 dwg, 7 tbl, 3 ex

Up!